Global Skin and Soft Tissue Infections Market is segmented By Type(Infected Ulcers, Wound Infections, Abscesses, Cellulitis, Otitis Externa, Others), By Drug Type (Antibiotics, Anti-fungal Agents, Others), By Route of Administration (Topical, Oral, Parenteral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031
Market Size
The Global Skin and Soft Tissue Infections Market reached US$ 11,283.71 million in 2023 and is expected to reach US$ 21,708.55 million by 2031, growing at a CAGR of 8.8% during the forecast period 2024-2031.
Skin and Soft Tissue Infections (SSTI) are infections of the skin, muscles, and connective tissue such as ligaments and tendons. The most frequent cause of SSTIs is bacteria, which can enter the body through a variety of openings such as burns, tiny cuts, scrapes, and wounds from surgical sites.
Common simple SSTIs include cellulitis, erysipelas, impetigo, ecthyma, folliculitis, furuncles, carbuncles, abscesses, and trauma-related infections. Complicated infections include deep abscesses, decubitus ulcers, necrotizing fasciitis, Fournier gangrene, and infections from human or animal bites.
Market Scope
|
Metrics |
Details |
|
CAGR |
8.8% |
|
Market Size Available for Years |
2022-2031 |
|
Estimation Forecast Period |
2024-2031 |
|
Revenue Units |
Value (US$ Mn) |
|
Segments Covered |
Type, Drug Type, Route of Administration, Distribution Channel |
|
Regions Covered |
North America, Europe, Asia-Pacific, South America, and Middle East & Africa |
|
Largest Region |
North America |
|
Fastest Growing Region |
Asia-Pacific |
|
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis and Other key Insights. |
For know more Insights - Download Sample
Market Dynamics: Drivers & Restraints
Rising product development and approvals
The rising developments and approvals of the drugs for the treatment of Skin and Soft Tissue Infections is expected to drive the market growth. With the development of new drugs there will be a wide range of products available for the individuals with the infections. This rises the demand for the new products for the treatment.
The rising product approvals with broad spectrum applications is expected to increase the demand for the drugs. For instance, in April 2024, the U.S. Food and Drug Administration approved Zevtera (ceftobiprole medocaril sodium for injection) for the treatment of adults with Staphylococcus aureus bloodstream infections (bacteremia) (SAB), including those with right-sided infective endocarditis, adults with acute bacterial skin and skin structure infections (ABSSSI).
Additionally, July 23, 2021, AbbVie received the U.S. Food and Drug Administration (FDA) approved DALVANCE (dalbavancin) for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in pediatric patients from birth. DALVANCE is the first single-dose option administered as a 30-minute intravenous (IV) infusion for the treatment of ABSSSI caused by designated susceptible Gram-positive bacteria in pediatric patients, including infections caused by methicillin-resistant Staphylococcus aureus (MRSA). Thus, the above factors could drive the market growth.
Resistance to the new strains of infectious bacteria
The emergence of antibiotic-resistant bacteria, such as vancomycin-resistant Enterococcus (VRE) and methicillin-resistant Staphylococcus aureus (MRSA), presents a major obstacle to the treatment of SSTIs. This reduces the effectiveness of conventional antibiotics, leading to extended therapy times, higher medical expenses, and worse patient outcomes.
Market Segment Analysis
The global Skin and Soft Tissue Infections market is segmented based on type, drug type, route of Administration, distribution channel and region.
Antibiotics segment is expected to dominate the market share
Antibiotics segment holds a major position in the market share. For bacterial SSTIs, antibiotics are currently the primary form of treatment. They function well against a variety of bacterial pathogens, including Streptococcus pyogenes and Staphylococcus aureus, that can lead to skin infections. Antibiotics specifically target bacterial infections, that are a common cause of SSTIs.
The large number of prescriptions for and treatments for bacterial infections has created an significant position for antibiotics.
The market position of antibiotics is further built by ongoing research and development activities in antibiotic therapy, which lead to the creation of novel formulations, combinations, and enhanced efficacy against antibiotic-resistant bacteria. Thus, the above factors are expected to drive the segment growth.
Market Geographical Share
North America is expected to hold a significant position in the skin and soft tissue infections market share
North America is holding a dominant position in the market share owing to the increasing incidence of several Skin and Soft Tissue Infections in the region. The presence of a large number of pharmaceutical companies in the region is also expected to be a factor in the growth of the region’s market.
The region has an advanced healthcare infrastructure with established hospitals and clinics. The hospitals and clinics have well-established diagnostic tools and the region also has well-established medical research and advancements in treatment options.
The increasing number of Skin and Soft Tissue Infections in the region increases demand for the new drugs that are developed in the region. For instance, according to the report by NIH in 2023, it is estimated that cellulitis is a very common skin infection that accounts for more than 14 million cases in the United States per year.
Additionally, according to the Agency for Healthcare Research and Quality, each year, more than 2.5 million people in the United States develop pressure ulcers. These skin lesions bring pain, associated risk for serious infection, and increased health care utilization. Pressure ulcers are associated with longer hospital stays and increased morbidity and mortality. Thus, the above factors are expected to hold the region in the dominant position.
Market Segmentation
By Type
- Infected Ulcers
- Wound Infections
- Abscesses
- Cellulitis
- Otitis Externa
- Others
By Drug Type
- Antibiotics
- Anti-fungal Agents
- Others
By Route of Administration
- Topical
- Oral
- Parenteral
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Others
By Region
- North America
- The U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe
- South America
- Brazil
- Argentina
- Rest of South America
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Middle East and Africa
Market Competitive Landscape
The major global players in the market include GSK Plc, Pfizer Inc., Merck KGaA, Wellona Pharma, GL Pharma, Basilea Pharmaceutica AG, Invision Medi Sciences Pvt. Ltd., Intelicure Lifesciences., Steris Healthcare Pvt Ltd and SNU Biocare among others.
Why Purchase the Report?
- To visualize the global skin and soft tissue infections market segmentation based on type, drug type, route of administration, distribution channel, and region as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerous data points of skin and soft tissue infections market-level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as Excel consisting of key products of all the major players.
The global skin and soft tissue infections market report would provide approximately 53 tables, 47 figures, and 176 pages.
Target Audience 2024
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
